Donor type, in Addition to Transplantation in Chronic Phase and Myeloablative Conditioning, Influence Transplant Survival for Patients with Advanced Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

Gelijkaardige items

• Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
  door: Kongtim, Piyanuch, et al.
  Gepubliceerd in: (2014)
• Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation
  door: Oran, Betul, et al.
  Gepubliceerd in: (2014)
• Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy
  door: Kongtim, Piyanuch, et al.
  Gepubliceerd in: (2015)
• Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation
  door: Bachegowda, Lohith S., et al.
  Gepubliceerd in: (2017)
• Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant -Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic syndrome
  door: Kongtim, Piyanuch, et al.
  Gepubliceerd in: (2018)